Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-21

Clinical Trial Update: ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating ABT-199 and Ibrutinib for Mantle Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABT-199 (venetoclax)
  • Ibrutinib (ibrutinib)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN